TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04443725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine , Sofosbuvir, daclatasvir
Description: Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol), Sofosbuvir 400 mg once daily for 14 days and daclatasvir 90 mg for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Hydroxychloroquine (hydroxychloroquine 400 mg by mouth twice daily for 1 day, then 200 mg by mouth twice daily for 14 days (dose reductions for weight \< 45 kg or GFR (glomerular filtration rate) \<50ml/min) alone; as provided by the MOHP protocol),
Study: NCT02632279

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stimulator ON
Description: Participants will be tested while their stimulator is turned ON

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator ON
Description: Participants will be tested while their stimulator is turned ON
Study: NCT04590365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carrageenan nasal and throat spray
Description: Iota-carrageenan nasal and throat spray (verum Coldamaris plus i.e. Iota-Carrageenan 0.12% plus 0.04% Kappa-Carrageenan in 0.5% saline)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline nasal and throat spray
Description: Saline nasal and throat spray (placebo Coldamaris sine i.e. 0.5% saline)
Study: NCT02632279

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stimulator OFF
Description: Participans will be tested while their stimulator is turned OFF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulator OFF
Description: Participans will be tested while their stimulator is turned OFF
Study: NCT04300127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Description: Patients will received 30 mg of Pioglitazone once a day for 8 weeks
Study: NCT02050776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Description: bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
Study: NCT01501617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hair Stimulating Complex (HSC)
Description: Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dulbecco's Modified Eagle Medium, DMEM
Description: Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
Study: NCT02300558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleclazine placebo
Description: Tablets administered orally
Study: NCT01937793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: effortful swallowing exercise
Description: voluntarily increases the posterior tongue base pushing effort while swallowing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mendelsohn swallowing exercise
Description: voluntarily increase the extent and duration of laryngeal elevation while swallowing
Study: NCT00905762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin
Description: Gatifloxacin 0.3% one drop instilled into study eye at visit 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin 0.5% one drop instilled into study eye at visit 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Besifloxacin
Description: Besifloxacin 0.6% one drop instilled into study eye at visit 2.
Study: NCT00813865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afegostat tartrate
Study: NCT02780635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App + Mailed Materials for managing stress associated with PTSD
Description: PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App for managing stress associated with PTSD
Description: PTSD Coach and PTSD Family Coach mobile apps

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile App for managing stress associated with PTSD
Description: PTSD Coach and PTSD Family Coach mobile apps
Study: NCT02660450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription for Workload
Description: Prescription from 65% VO2max for 5 min of exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription for Workload
Description: Prescription from 65% VO2max for 5 min of exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription for Heart Rate
Description: Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription for Heart Rate
Description: Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription Self Selected
Description: Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription Self Selected
Description: Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
Study: NCT03910738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
Description: Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4 mL Solution for Injection
Description: Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
Description: BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities
Description: BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Assessment of disability
Description: EDSS (Baseline, week 30 and 66)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment of disability
Description: EDSS (Baseline, week 30 and 66)
Study: NCT03505788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
Study: NCT00613002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: once daily transdermal testosterone gel, 300 mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: once daily transdermal placebo gel
Study: NCT00998413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Description: multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
Study: NCT01887275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: medical ozone therapy with humares
Description: Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg \~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional interferon-α
Description: Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
Study: NCT03871439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 Formulation A
Description: 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304 Formulation B
Description: 50mg
Study: NCT02226159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine with Dexamethasone
Study: NCT02113826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib 800mg qd daily for 4 weeks = 1 cycle
Study: NCT02429492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiology
Description: EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiology
Description: EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
Study: NCT04955483

Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual single energy combined with MAR reconstruction group
Description: combined with MAR reconstruction group
Study: NCT02833753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy . Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 4: Oxaliplatin 55 mg/m2 IP every 2 weeks on day #1 of chemotherapy (due to DLTs found)
Study: NCT02307097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Bibliotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WAIT
Study: NCT03579472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study: NCT01714206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin 0.5 mg
Description: Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.5 mg
Description: Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin 0.25 mg
Description: One 0.25 mg tablet taken orally on Days 2 through 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg
Description: One 0.25 mg tablet taken orally on Days 2 through 7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 300 mg tablet taken orally on Days 1 through 7.
Study: NCT01301521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: water-soluble cinnamon extract (Cinnulin PF)
Description: Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: water-soluble cinnamon extract (Cinnulin PF)
Description: Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
Study: NCT02121106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Remediation
Study: NCT00005901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate (Aredia)
Description: Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pamidronate (Aredia)
Description: Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
Study: NCT04254367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learn-to-Cope
Description: Patient education in study circles, aiming to empower patients to participate in health care and rehabilitation by increasing health literacy and sense of coherence. The study circles will meet half a day each week for eight following weeks.
Study: NCT01480414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4times injection
Description: bone marrow derived mono nuclear stem cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
Study: NCT02647541

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
Study: NCT03371134

Intervention type: BIOLOGICAL
Intervention: Harvesting of muscular biopsies
Description: Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.

Intervention type: BIOLOGICAL
Intervention: Harvesting of muscular biopsies
Description: Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
Study: NCT01748526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 200 mg
Description: One 200 mg tablet taken orally (by mouth) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 300 mg
Description: One 300 mg tablet taken orally (by mouth) on Day 1.
Study: NCT03402971

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: echocardiography
Description: echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
Study: NCT01978249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary tumor resection (PTR)
Description: primary tumor resection (PTR) using open or laparoscopy or robotic surgery
Study: NCT02906449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Technique
Description: Alertness training or relaxation training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meditation Technique
Description: Alertness training or relaxation training
Study: NCT02681796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study: NCT03960086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Podoactiva cutom-made foot orthoses
Description: Children had to use the orthotics daily during the intervention period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Podoactiva heel lifts
Description: Children had to use the orthotics daily during the intervention period
Study: NCT02231411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: V-DCC
Description: Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: Delayed clamping of the umbilical cord for 60 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels
Study: NCT02095665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: 50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: 50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol #3
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol #3
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol #3
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tylenol #3
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
Study: NCT02479165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofene
Description: The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: The opioid group is given an oxycodone based analgesic regimen.
Study: NCT02748434

Intervention type: OTHER
Group type: OTHER
Intervention: Lipohypertrophy

Intervention type: OTHER
Group type: OTHER
Intervention: Normal Subcutaneous Tissue
Study: NCT01774097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD-301
Description: Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Ten 1ml injections of placebo in the index calf and posterior, lower thigh
Study: NCT01872039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perdipine injection
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perdipine injection
Description: IV
Study: NCT02813655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracosactide (Synacthène®)
Description: Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo saline (0.9% NaCl)
Description: placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15.
Study: NCT01741142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: Subjects receiving ABT-436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Subjects receiving escitalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject receiving placebo
Study: NCT03896724

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 adjuvanted with 25mcg Matrix-M
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies Vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 adjuvanted with 50mcg Matrix-M
Description: vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 adjuvanted with 50mcg Matrix-M
Description: vaccine